You searched for "DMEK"
Descemet stripping endothelial keratoplasty: surgical management of congenital hereditary endothelial dystrophy
This retrospective case series reports the long-term outcomes of Descemet stripping endothelial keratoplasty (DSEK) with suture assisted donor lenticular assisted donor lenticule insertion in paediatric patients with congenital hereditary endothelial dystrophy (CHED). Thirty eyes of 16 patients were reviewed and...
Scheimpflug images and graft rejection
This study aimed to assess corneal changes using 360-degree Scheimpflug images and pachymetry readings to outline screening parameters, which define graft rejection. Seventeen eyes of 16 patients developed clinically manifest allograft rejection two to 42 months after surgery – those...
Insights in resistant diabetic macular oedema
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...
DSEK – five year results
This UK based study examined long-term descemet stripping endothelial keratoplasty (DSEK) results, looking at graft survival and endothelial cell losses. Data on 210 grafts were included in analysis. Most frequent indication for DSEK was Fuch’s endothelial dystrophy (81.4%) and 46.3%...
Ripasudil after Descemet stripping in Fuch’s endothelial dystrophy
This study prospectively evaluated the use of ripasudil, a rho kinase inhibitor, in patients undergoing Descemet’s stripping only (DSO) without an endothelial graft for Fuch’s endothelial dystrophy (FED). Patients with dense central guttae limited to the central 5mm of the...
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
Intravitreal dexamethasone implant for diabetic macular oedema
The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...
Treatment of diabetic macular edema in vitrectomised eyes – comparison of intravitreal dexamethasone implant and posterior subtenon triamcinolone injection
This retrospective study was aimed to compare intravitreal dexamethasone implant and posterior subtenon triamcinolone injection (PSTA) in the treatment of diabetic macular edema (DME) in vitrectomised eyes. Sixty-four (48.12%) patients who had received PSTA and 69 (51.88%) patients who had...Corneal dystrophies simplified
Based on biomicroscopic and histopathologic features, corneal dystrophies can be broadly classified into epithelial, Bowman’s layer / anterior stromal, stromal, and endothelial dystrophies. Corneal dystrophies are a group of inherited, bilateral, gradually progressing, non- inflammatory conditions caused by accumulation of...In conversation with Christopher Liu OBE
Eye News caught up with Christopher Liu following his recent appointment by Her Majesty Queen Elizabeth II as an Officer of the Most Excellent Order of the British Empire for Services to Ophthalmology. Christopher Liu OBE. Congratulations on your recent...
Macular oedema after cataract surgery in diabetic patients
The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...
